Rapid resolution of psychotic symptoms in a patient with schizophrenia using allopurinol as an adjuvant: A case report

Clinical Schizophrenia and Related Psychoses

Volumn 7, Issue 4, 2014, Pages 231-234

  Linden, Noah ^a   Onwuanibe, Angela ^b   Sandson, Neil ^a  

^a VAMHCS   (United States)

^b Clifton T Perkins Hospital Center   (United States)

Author keywords

Allopurinol; Schizophrenia

Indexed keywords

ALLOPURINOL; BENZATROPINE; CHLORPROMAZINE; CLOZAPINE; FLUOXETINE; HALOPERIDOL; LITHIUM; LORAZEPAM; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PALIPERIDONE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

ADJUVANT THERAPY; ADULT; AFRICA; ANTISOCIAL BEHAVIOR; ARTICLE; AUDITORY HALLUCINATION; BEHAVIOR CHANGE; BLOOD CELL COUNT; BLUNTED AFFECT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DAILY LIFE ACTIVITY; DELUSION; DRUG WITHDRAWAL; EMERGENCY HEALTH SERVICE; EPILEPSY; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MALE; MEDICAL HISTORY; NEUROIMAGING; NEUTROPHIL COUNT; NIGERIA; OCCUPATIONAL THERAPY; OUTPATIENT CARE; PERSONAL HYGIENE; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA; SELF CARE; SLEEP; UNITED STATES; VISUAL HALLUCINATION;

ALLOPURINOL; SCHIZOPHRENIA;

ADULT; ALLOPURINOL; ANTIPSYCHOTIC AGENTS; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FREE RADICAL SCAVENGERS; HUMANS; MALE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 84892615860     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.LION.020113     Document Type: Article

References (11)

1. Freedman R. Schizophrenia. N Engl J Med 2003;349(18):1738-1749. (Pubitemid 37315012)
2. Buie LW, Oertel MD, Cala SO. Allopurinol as adjuvant therapy in poorly responsive or treatment refractory schizophrenia. Ann Pharmacother 2006;40(12):2200-2204. (Pubitemid 44954440)
3. Lara DR, Dall'Igna OP, Ghisolfi ES, Brunstein MG. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications. Prog Neuropsychopharmacol Biol Psychiatry 2006;30(4):617-629.
4. Ferre S. Adenosine-dopamine interactions in the ventral striatum: implications for the treatment of schizophrenia. Psychopharmacology 1997;133(2):107-120. (Pubitemid 27404740)
5. Lara DR, Brunstein MG, Ghisolfi ES, Lobato MI, Belmonte-de-Abreu P, Souza DO. Allopurinol augmentation for poorly responsive schizophrenia. Int Clin Psychopharmacol 2001;16(4):235-237. (Pubitemid 32612522)
6. Liang CS, Yang FW, Chiang KT, Ho PS. Allopurinol for treatment-resistant schizophrenia and epilepsy: a case report. Pharmacopsychiatry 2010;43(6):233-234.
7. Akhondzadeh S, Safarcherati A, Amini H. Beneficial antipsychotic effects of allopurinol as add-on therapy for schizophrenia: a double blind, randomized and placebo controlled trial. Prog Neuropsychopharmacol Biol Psychiatry 2005;29(2):253-259. (Pubitemid 40202911)
8. Brunstein MG, Ghisolfi ES, Ramos FL, Lara DR. A clinical trial of adjuvant allopurinol therapy for moderately refractory schizophrenia. J Clin Psychiatry 2005;66(2):213-219. (Pubitemid 40314328)
9. Dickerson FB, Stallings CR, Origoni AE, Sullens A, Khushalani S, Sandson N, et al. A double-blind trial of adjunctive allopurinol for schizophrenia. Schizophr Res 2009;109(1-3):66-69.
10. Brenner HD, Dencker SJ, Goldstein MJ, Hubbard JW, Keegan DL, Kruger G, et al. Defining treatment refractoriness in schizophrenia. Schizophr Bull 1990;16(4):551-561.
11. Agid O, Seeman P, Kapur S. The "delayed" onset of antipsychotic action - an idea whose time has come and gone. J Psychiatry Neurosci 2006;31(2):93-100.